- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
PharmaLex Opens New Branch In China
The new office will give clients access to the company's services in the Chinese market.
PharmaLex Group, a provider of specialized services for the pharma, biotech, and medtech industries worldwide, has announced the opening of a new branch in Beijing, China, giving global clients access to a team of regulatory experts in the region.
As of September 2022, the newly established PharmaLex Beijing team, which includes personnel joining from Bayer China, will be offering pharmacovigilance, regulatory affairs, development consulting, and quality management to global clients bringing products to the China market. PharmaLex China will also be the local contact point for Chinese-based biopharmaceutical companies that are developing pharmaceuticals or medical devices with a goal of entering the European or US markets.
Continue reading here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
